Medi-Mibi (Technetium (99mtc) Sestamibi)

Technetium (99mTc) sestamibi, the active ingredient in Medi-Mibi, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is employed for myocardial perfusion imaging and cardiac stress testing in patients undergoing evaluation of coronary artery disease.

GNH USA supplies Medi-Mibi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, cardiac imaging centres and diagnostic clinics worldwide.

Medi-Mibi is used in cardiac imaging to assess myocardial blood flow and detect ischemia.

Myocardial perfusion imaging: provides visual assessment of regional blood flow to identify areas of reduced perfusion. Cardiac stress testing: enables evaluation of heart function under pharmacologic or exercise stress conditions. Coronary artery disease assessment: helps detect obstructive lesions by highlighting perfusion defects. Evaluation of ventricular function: assists in quantifying left ventricular ejection fraction during gated SPECT studies.

Medi-Mibi may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache. - Flushing: temporary warmth or redness of the skin.

Serious or Rare Side Effects: - Allergic reaction (anaphylaxis): severe hypersensitivity requiring immediate medical attention. - Radiation‑induced skin injury: localized skin changes at high exposure sites. - Severe hypotension: marked drop in blood pressure, potentially requiring intervention.

Prior to using Medi-Mibi, consider the following safety measures.

Pregnancy: assess risk versus benefit; use only if essential for maternal care. Breastfeeding: consider discontinuing nursing or evaluate infant exposure risk. Renal impairment: monitor because reduced clearance may increase radiation exposure. Thyroid disorders: avoid in patients with hyperthyroidism due to possible tracer uptake. Radiation safety: follow institutional protocols to limit staff and patient exposure. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Medi-Mibi may interact with other agents that affect tracer distribution or radiation exposure.

Major Interactions (Avoid): - Thyroid blocking agents (e.g., potassium iodide): may alter biodistribution of the tracer. - Other radiopharmaceuticals administered within 24 h: can lead to cumulative radiation dose. - Chemotherapeutic agents affecting mitochondrial function: may interfere with tracer uptake.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt heart‑rate response during stress testing. - Calcium channel blockers: may influence myocardial perfusion patterns. - Sedatives: can affect patient cooperation during image acquisition.